U.S. markets close in 5 hours 56 minutes
  • S&P 500

    4,149.96
    -14.04 (-0.34%)
     
  • Dow 30

    34,135.31
    -21.38 (-0.06%)
     
  • Nasdaq

    12,041.24
    -72.55 (-0.60%)
     
  • Russell 2000

    1,965.55
    -7.06 (-0.36%)
     
  • Crude Oil

    77.74
    +0.60 (+0.78%)
     
  • Gold

    1,884.50
    -0.30 (-0.02%)
     
  • Silver

    22.29
    +0.11 (+0.51%)
     
  • EUR/USD

    1.0725
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    3.6730
    -0.0010 (-0.03%)
     
  • GBP/USD

    1.2064
    +0.0012 (+0.10%)
     
  • USD/JPY

    131.3700
    +0.2980 (+0.23%)
     
  • BTC-USD

    23,063.92
    +82.34 (+0.36%)
     
  • CMC Crypto 200

    532.64
    -4.25 (-0.79%)
     
  • FTSE 100

    7,909.91
    +45.20 (+0.57%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Aequus Announces Short Term Loan

Aequus Pharmaceuticals
Aequus Pharmaceuticals

VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that it has entered into an agreement with Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, pursuant to which Mr. Janzen will provide short-term financing to Aequus by way of an unsecured demand loan of C$2 million (the “Loan”). The purpose of the financing is to allow the Company to pay off the existing convertible debentures maturing May 2, 2022.

Grant Larsen, Aequus’ Chief Commercial Officer, stated: “We are thankful for Doug’s investment. His continued confidence in our ability to provide cost-effective and high-quality solutions to meet both patient and physician needs. The proceeds from the note will enable us to repay the convertible debentures maturing in May and allow us to focus our efforts on our strongest product candidates, reaffirming our commercial capabilities, and rejuvenating specialty products and categories for our partners.”

“I see lot of opportunities for Aequus to continue to add new products to our portfolio. This loan agreement supports future growth and materially lowers our interest costs,” said Doug Janzen, Aequus Chairman and CEO. “We are excited about our future as Zimed PF is making steady progress though the Health Canada review process and our team continues to work toward adding new Eye Care products, including products from our partners at ReVision.”

The Loan will bear interest at an annual rate of interest of two and a half percent (2.5%), to be calculated and repaid monthly, and is repayable on demand.

The Company and Mr. Janzen are also working towards a longer-term financing arrangement that will replace the Loan.

The Loan involves a related party (as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”)), specifically a director and senior officer of the Company, and constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(b) and 5.7(1)(f) of MI 61-101, as the Company is not listed or quoted on any of the stock exchanges or markets listed in subsection 5.5(b) of MI 61-101, and the Loan represents a loan from a related party on reasonable commercial terms that are not less advantageous to the Company than if the Loan were obtained from a person dealing at arm’s length and the Loan is not convertible or repayable in securities.

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

Forward-Looking Statements

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the use of proceeds from the Loan; the potential for a further financing arrangement between the Company and Mr. Janzen; and the implementation of our business model and strategic plans. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s final short-form prospectus dated November 5, 2021, and annual information form dated April 30, 2021, copies of which are available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906